Literature DB >> 16606362

Caspase-dependent alteration of the ADP/ATP translocator triggers the mitochondrial permeability transition which is not required for the low-potassium-dependent apoptosis of cerebellar granule cells.

Anna Atlante1, Antonella Bobba, Lidia de Bari, Fabrizio Fontana, Pietro Calissano, Ersilia Marra, Salvatore Passarella.   

Abstract

We investigated ADP/ATP exchange mediated by the adenine nucleotide translocator and opening of the mitochondrial permeability transition pore in homogenates from cerebellar granule cells en route to apoptosis induced by low potassium. We showed that, in the first 3 h of apoptosis, when maximum cytochrome c release had already occurred, adenine nucleotide translocator function was impaired owing to the action of reactive oxygen species, but no permeability transition pore opening occurred. Over 3-8 h of apoptosis, the permeability transition pore progressively opened, owing to caspase action, and further ADP/ATP translocator impairment occurred. The kinetics of transport and permeability transition pore opening were inversely correlated, both in the absence and presence of inhibitors of antioxidant and proteolytic systems. We conclude that, en route to apoptosis, alteration of the adenine nucleotide translocator occurs, resulting in permeability transition pore opening. This process depends on the action of caspase on pore component(s) other than the ADP/ATP translocator, because no change in either amount or molecular weight of the latter protein was noted during apoptosis, as measured by western blotting. Cell death occurs via apoptosis in the presence of cyclosporin A, the permeability transition pore inhibitor, thus showing that permeability transition pore opening, not needed for cytochrome c release, is also unnecessary for apoptosis to occur.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606362     DOI: 10.1111/j.1471-4159.2006.03820.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Functional characterization of the oxidative capacity of mitochondria and glycolytic assessment in benthic aquatic organisms.

Authors:  A Atlante; A Basset; A Bobba; R Lassandro; F Mastrototaro; F Vignes
Journal:  J Bioenerg Biomembr       Date:  2016-02-04       Impact factor: 2.945

2.  Mitochondrial dysfunction induced by sertraline, an antidepressant agent.

Authors:  Yan Li; Letha Couch; Masahiro Higuchi; Jia-Long Fang; Lei Guo
Journal:  Toxicol Sci       Date:  2012-03-02       Impact factor: 4.849

3.  Modulation of glucose-related metabolic pathways controls glucose level in airway surface liquid and fight oxidative stress in cystic fibrosis cells.

Authors:  M Favia; L de Bari; R Lassandro; Anna Atlante
Journal:  J Bioenerg Biomembr       Date:  2019-04-27       Impact factor: 2.945

4.  Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease.

Authors:  Antonella Bobba; Vito A Petragallo; Ersilia Marra; Anna Atlante
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

5.  Characterization of mitochondrial function in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function.

Authors:  Anna Atlante; Maria Favia; Antonella Bobba; Lorenzo Guerra; Valeria Casavola; Stephan Joel Reshkin
Journal:  J Bioenerg Biomembr       Date:  2016-05-05       Impact factor: 2.945

Review 6.  Dysfunction of Mitochondria in Alzheimer's Disease: ANT and VDAC Interact with Toxic Proteins and Aid to Determine the Fate of Brain Cells.

Authors:  Anna Atlante; Daniela Valenti; Valentina Latina; Giuseppina Amadoro
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

Review 7.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.